Payment overview · 2025
General Payments
$594.02
25 reported records · 16 companies
Healthcare provider profile · identity verified
Christopher Mcilwain, DO
Allopathic & Osteopathic Physicians|Family Medicine · ALBUQUERQUE, NM · NPI 1063528719
Verified facts
What the public records show
CMS Open Payments records show Christopher Mcilwain, DO received $594.02 in general payments during 2025 across 25 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $99.55 | 16.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.35 | 12.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.32 | 11.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.70 | 10.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.99 | 8.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.64 | 5.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.03 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.62 | 4.7% | 2 | 2025 |
| CooperSurgical, Inc. | Unresolved — no canonical attribution shown | $22.22 | 3.7% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $22.02 | 3.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.17 | 3.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.72 | 3.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.18 | 3.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.65 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.37 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.49 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $594.02 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $99.55 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $68.17 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $59.70 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.64 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.62 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.62 | 2 | 2025 |
Source payment records
|
|||||
| Paragard T 380A Normalized: paragard t 380a |
Drug | CooperSurgical, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 456 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 438 | 141 |
| Lisinopril | Lisinopril | 402 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 369 | 118 |
| Gabapentin | Gabapentin | 303 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 254 | 86 |
| Losartan Potassium | Losartan Potassium | 252 | 78 |
| Metformin Hcl | Metformin Hcl | 217 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 69 |
| Alendronate Sodium | Alendronate Sodium | 193 | 53 |
| Omeprazole | Omeprazole | 169 | 59 |
| Ezetimibe | Ezetimibe | 160 | 51 |
| Allopurinol | Allopurinol | 147 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 40 |
| Famotidine | Famotidine | 112 | 42 |
| Tramadol Hcl | Tramadol Hcl | 109 | 32 |
| Donepezil Hcl | Donepezil Hcl | 102 | 26 |
| Lovastatin | Lovastatin | 98 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 33 |
| Simvastatin | Simvastatin | 93 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 29 |
| Montelukast Sodium | Montelukast Sodium | 79 | 23 |
| Trazodone Hcl | Trazodone Hcl | 77 | 29 |
| Carvedilol | Carvedilol | 75 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 21 |
| Pregabalin | Pregabalin | 67 | 13 |
| Sertraline Hcl | Sertraline Hcl | 66 | 19 |
| Metformin Hcl Er | Metformin Hcl | 65 | 20 |
| Mirtazapine | Mirtazapine | 65 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 18 |
| Baclofen | Baclofen | 60 | 22 |
| Farxiga | Dapagliflozin Propanediol | 56 | 17 |
| Spiriva Respimat | Tiotropium Bromide | 55 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 19 |
| Glipizide Er | Glipizide | 53 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 51 | 12 |
| Meloxicam | Meloxicam | 47 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 13 |
| Furosemide | Furosemide | 46 | 19 |
| Memantine Hcl | Memantine Hcl | 46 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 20 |
| Eliquis | Apixaban | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 14 |
| Prednisone | Prednisone | 43 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Finasteride | Finasteride | 39 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 11 |
| Xarelto | Rivaroxaban | 37 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 12 |
| Nitroglycerin | Nitroglycerin | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 11 |
| Cephalexin | Cephalexin | 24 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Atenolol | Atenolol | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 14 |
| Ozempic | Semaglutide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Alogliptin | Alogliptin Benzoate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Diazepam | Diazepam | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 14 | 11 |
| Azithromycin | Azithromycin | 13 | 13 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Rezvoglar Kwikpen | Insulin Glargine-Aglr | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $594.02 · 25 records | SANOFI-AVENTIS U.S. LLC | ABRYSVO, BREZTRI, COMIRNATY, CRYSVITA, EVENITY, JARDIANCE, MOUNJARO, NURTEC ODT, PENBRAYA, PREVNAR 20, Paragard T 380A, REXULTI, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, Veozah, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error